Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma

Girum L. Lemma, Ju Whei Lee, Seena C. Aisner, Corey J. Langer, William J. Tester, David H. Johnson, Patrick J. Loehrer

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9%; 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95% CI, 7.2 to 19.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) with thymic carcinoma. Median survival time was 20.0 months (95% CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma. Conclusion: Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.

Original languageEnglish (US)
Pages (from-to)2060-2065
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number15
DOIs
StatePublished - May 20 2011

Fingerprint

Thymoma
Carboplatin
Paclitaxel
Disease-Free Survival
Survival
Anthracyclines
Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lemma, G. L., Lee, J. W., Aisner, S. C., Langer, C. J., Tester, W. J., Johnson, D. H., & Loehrer, P. J. (2011). Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. Journal of Clinical Oncology, 29(15), 2060-2065. https://doi.org/10.1200/JCO.2010.32.9607

Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. / Lemma, Girum L.; Lee, Ju Whei; Aisner, Seena C.; Langer, Corey J.; Tester, William J.; Johnson, David H.; Loehrer, Patrick J.

In: Journal of Clinical Oncology, Vol. 29, No. 15, 20.05.2011, p. 2060-2065.

Research output: Contribution to journalArticle

Lemma, GL, Lee, JW, Aisner, SC, Langer, CJ, Tester, WJ, Johnson, DH & Loehrer, PJ 2011, 'Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma', Journal of Clinical Oncology, vol. 29, no. 15, pp. 2060-2065. https://doi.org/10.1200/JCO.2010.32.9607
Lemma, Girum L. ; Lee, Ju Whei ; Aisner, Seena C. ; Langer, Corey J. ; Tester, William J. ; Johnson, David H. ; Loehrer, Patrick J. / Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 15. pp. 2060-2065.
@article{8d6a8d28593f4a14a2d958879a823437,
title = "Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma",
abstract = "Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9{\%}; 90{\%} CI, 24.5{\%} to 62.8{\%}) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7{\%}; 90{\%} CI, 9.0{\%} to 40.4{\%}) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95{\%} CI, 7.2 to 19.8) and 5.0 (95{\%} CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3{\%}) with thymoma have died, compared with 16 patients (69.6{\%}) with thymic carcinoma. Median survival time was 20.0 months (95{\%} CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma. Conclusion: Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.",
author = "Lemma, {Girum L.} and Lee, {Ju Whei} and Aisner, {Seena C.} and Langer, {Corey J.} and Tester, {William J.} and Johnson, {David H.} and Loehrer, {Patrick J.}",
year = "2011",
month = "5",
day = "20",
doi = "10.1200/JCO.2010.32.9607",
language = "English (US)",
volume = "29",
pages = "2060--2065",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma

AU - Lemma, Girum L.

AU - Lee, Ju Whei

AU - Aisner, Seena C.

AU - Langer, Corey J.

AU - Tester, William J.

AU - Johnson, David H.

AU - Loehrer, Patrick J.

PY - 2011/5/20

Y1 - 2011/5/20

N2 - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9%; 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95% CI, 7.2 to 19.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) with thymic carcinoma. Median survival time was 20.0 months (95% CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma. Conclusion: Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.

AB - Purpose: The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. Patients and Methods We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. Results: From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9%; 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95% CI, 7.2 to 19.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) with thymic carcinoma. Median survival time was 20.0 months (95% CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma. Conclusion: Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.

UR - http://www.scopus.com/inward/record.url?scp=79956310069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956310069&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.32.9607

DO - 10.1200/JCO.2010.32.9607

M3 - Article

VL - 29

SP - 2060

EP - 2065

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -